ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
CARSON CITY, Nev., Dec. 06, 2022 BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced. | December 6, 2022
- Investigator Sponsored Trial sites in Australia include St. Vincent s Hospital, Sydney, Alfred Health, Melbourne, and the Royal Victorian Eye and Ear.
.
The rESPECT IST (NCT04292743) is a single arm, dose escalating Phase 1 clinical trial to evaluate the safety of eryaspase in combination with modified FOLFIRINOX. The trial is conducted by Dr Marcus Noel, Associate Professor of Medicine at Georgetown University, Washington DC, USA, and will enroll approximately 18 patients who have received no prior chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer. FOLFIRINOX is one of the most commonly utilized first-line chemotherapy regimens for the treatment of pancreatic cancer, despite its toxicity.
The trial was launched at the end of last year and has now enrolled the first cohort of three patients. After review of the safety data, the Dose Escalation Committee concluded that no dose-limiting toxicity (DLT) had been observed in the first cohort treated at a therapeutic dose of 75 U/kg eryaspase, and as of the date of this press release, treatment was observed to be well tolerated in the cohort.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of .
Erytech Pharma S.A.April 19, 2021 GMT
ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
No dose-limiting toxicity reported in the first dose cohort
Encouraging clinical activity observed in first patients
Trial will be escalated to the next dose
Lyon (France) and Cambridge, MA (U.S.), April 19, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the completion of enrollment of the first treatment cohort and the escalation to the next and potentially final dose level in a Phase 1 investigator sponsored clinical trial (IST), named rESPECT, of its lead pro